Prelude Therapeutics (PRLD) Institutional Ownership $1.31 +0.03 (+2.34%) Closing price 04:00 PM EasternExtended Trading$1.32 +0.00 (+0.38%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Prelude Therapeutics (NASDAQ:PRLD)CurrentInstitutional OwnershipPercentage79.72%Number ofInstitutional Buyers(last 12 months)24TotalInstitutional Inflows(last 12 months)$5.98MNumber ofInstitutional Sellers(last 12 months)7TotalInstitutional Outflows(last 12 months)$475.07K Get PRLD Insider Trade Alerts Want to know when executives and insiders are buying or selling Prelude Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data PRLD Institutional Buying and Selling by Quarter Prelude Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Shay Capital LLC75,000$61K0.0%N/A0.133% 8/14/2025 Jane Street Group LLC91,753$74K0.0%N/A0.163% 8/13/2025 Marshall Wace LLP41,747$34K0.0%N/A0.074% 8/12/2025 XTX Topco Ltd42,573$34K0.0%+72.4%0.075% 8/8/2025 Geode Capital Management LLC217,568$176K0.0%-46.3%0.385% 8/1/2025 Y Intercept Hong Kong Ltd47,788$39K0.0%N/A0.085% 5/21/2025 Acadian Asset Management LLC529,327$405K0.0%+9.1%0.938% 5/16/2025 AQR Capital Management LLC33,823$26K0.0%+170.7%0.078% 5/12/2025 Simplex Trading LLC41,846$32K0.0%+121.2%0.096% 5/9/2025 Deutsche Bank AG80,723$62K0.0%-34.8%0.185% Get the Latest News and Ratings for PRLD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/17/2025 Two Sigma Investments LP231,839$296K0.0%+307.2%0.421% 2/17/2025 Two Sigma Advisers LP300,000$382K0.0%+526.3%0.545% 2/17/2025 Millennium Management LLC462,555$590K0.0%+188.2%0.841% 2/17/2025 Jacobs Levy Equity Management Inc.666,574$850K0.0%+280.9%1.211% 2/17/2025 Deutsche Bank AG123,899$159K0.0%+747.6%0.225% 2/17/2025 Bridgeway Capital Management LLC111,000$142K0.0%-37.0%0.202% 2/17/2025 BNP Paribas Financial Markets20,572$26K0.0%N/A0.037% 2/14/2025 Boxer Capital Management LLC1,708,187$2.18M0.2%N/A3.104% 2/14/2025 Northern Trust Corp83,387$106K0.0%-21.6%0.152% 2/14/2025 Price T Rowe Associates Inc. MD1,029,199$1.31M0.0%-6.2%1.870% 2/13/2025 Marshall Wace LLP392,155$498K0.0%+9.2%0.713% 2/13/2025 Renaissance Technologies LLC634,500$809K0.0%+222.2%1.153% 2/12/2025 Massachusetts Financial Services Co. MA494,497$630K0.0%-10.0%0.899% 2/12/2025 JPMorgan Chase & Co.61,149$78K0.0%+925.0%0.111% 2/6/2025 Charles Schwab Investment Management Inc.117,200$149K0.0%-12.0%0.213% 1/30/2025 Rhumbline Advisers166,830$213K0.0%+1,289.8%0.303% 11/19/2024 Barclays PLC27,165$57K0.0%+86.0%0.049% 11/16/2024 Geode Capital Management LLC391,716$811K0.0%+8.2%0.712% 11/15/2024 Barclays PLC27,165$57K0.0%+86.0%0.049% 11/15/2024 XTX Topco Ltd48,239$100K0.0%N/A0.088% 11/15/2024 State Street Corp286,046$592K0.0%+35.1%0.520% 11/15/2024 Jacobs Levy Equity Management Inc.174,979$362K0.0%+885.2%0.318% 11/14/2024 Walleye Capital LLC83,175$172K0.0%+446.2%0.151% 11/12/2024 Massachusetts Financial Services Co. MA549,530$1.14M0.0%+5.2%0.999% 10/10/2024 Exchange Traded Concepts LLC64,409$133K0.0%+32.2%0.153% 8/15/2024 The Manufacturers Life Insurance Company70,045$267K0.0%-3.1%0.166% 8/9/2024 Renaissance Technologies LLC206,600$787K0.0%-15.6%0.491% 8/9/2024 Dimensional Fund Advisors LP29,074$111K0.0%+103.2%0.069% 8/9/2024 Massachusetts Financial Services Co. MA522,375$1.99M0.0%+2.8%1.241% 7/26/2024 Bank of New York Mellon Corp36,276$138K0.0%-9.5%0.086% BREAKING: The House just passed 3 pro-crypto bills! (Ad)THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Discover the under-the-radar project I believe will skyrocket as a result.5/16/2024 Kennedy Capital Management LLC25,035$119K0.0%N/A0.059% 5/15/2024 Price T Rowe Associates Inc. MD941,971$4.47M0.0%-9.7%2.239% 5/10/2024 Acadian Asset Management LLC22,110$104K0.0%+42.7%0.053% 5/10/2024 Vanguard Group Inc.1,016,999$4.82M0.0%+1.0%2.417% 2/15/2024Boxer Capital LLC2,568,287$10.97M0.5%+2.9%4.684% 2/14/2024 Pale Fire Capital SE63,581$271K0.0%+106.6%0.116% 1/12/2024 SG Americas Securities LLC13,100$56K0.0%N/A0.024% 1/5/2024 Exchange Traded Concepts LLC44,087$188K0.0%+34.0%0.080% 11/14/2023 Pale Fire Capital SE30,781$95K0.0%N/A0.056% 11/13/2023 FMR LLC5,131,433$15.86M0.0%-13.6%9.359% 11/7/2023 Barclays PLC13,316$42K0.0%+120.0%0.024% 10/27/2023 TD Asset Management Inc160,652$496K0.0%+100.0%0.293% 10/18/2023 Exchange Traded Concepts LLC32,907$102K0.0%+29.4%0.060% 9/21/2023 Barclays PLC6,052$27K0.0%-41.4%0.011% 8/15/2023Boxer Capital LLC2,495,018$11.23M0.5%+256.9%4.552% 8/9/2023 TD Asset Management Inc80,326$361K0.0%+182.4%0.147% 7/20/2023 Exchange Traded Concepts LLC25,428$114K0.0%N/A0.053% 5/16/2023Boxer Capital LLC699,047$3.99M0.2%N/A1.458% 5/1/2023 Virtu Financial LLC11,201$64K0.0%N/A0.023% 2/14/2023 683 Capital Management LLC28,631$173K0.0%N/A0.060% 2/13/2023 GSA Capital Partners LLP47,801$289K0.0%-11.8%0.100% 2/10/2023 New York Life Investment Management LLC82,000$495K0.0%+11.7%0.171% 2/9/2023 Citigroup Inc.60,072$363K0.0%+604.1%0.126% 2/7/2023 Bleakley Financial Group LLC22,325$135K0.0%N/A0.047% 11/15/2022Caxton Associates LP85,992$568K0.1%+2.5%0.180% 11/14/2022 PDT Partners LLC12,641$84K0.0%-71.1%0.026% 11/9/2022 Massachusetts Financial Services Co. MA513,293$3.39M0.0%+7.3%1.073% 10/25/2022 Denali Advisors LLC8,200$54K0.0%N/A0.017% 8/16/2022 Corton Capital Inc.15,586$81K0.1%+42.8%0.033% 8/16/2022Delphia USA Inc.16,940$88K0.1%N/A0.035% 8/13/2022 Massachusetts Financial Services Co. MA478,525$2.50M0.0%-0.7%1.000% 8/12/2022 Virtus ETF Advisers LLC24,005$125K0.0%+84.0%0.050% 7/19/2022 Commonwealth Equity Services LLC16,617$86K0.0%-18.8%0.035% 5/11/2022 Massachusetts Financial Services Co. MA482,119$3.33M0.0%+2.8%1.012% 5/11/2022 GSA Capital Partners LLP23,201$160K0.0%N/A0.049% 5/6/2022IndexIQ Advisors LLC56,750$392K0.0%N/A0.119% 5/5/2022 New York State Common Retirement Fund4,992$34K0.0%-45.1%0.010% 5/4/2022 Commonwealth Equity Services LLC20,467$141K0.0%-10.4%0.043% 3/3/2022 Walleye Capital LLC41,954$522K0.0%N/A0.089% 2/14/2022 PDT Partners LLC35,907$447K0.0%N/A0.076% 2/14/2022 Virtus ETF Advisers LLC13,815$172K0.1%+119.6%0.029% 2/14/2022 Point72 Hong Kong Ltd3,872$48K0.0%+141.7%0.008% 2/11/2022 Ensign Peak Advisors Inc8,080$101K0.0%N/A0.017% 2/11/2022 Parkwood LLC12,667$158K0.0%N/A0.027% 2/10/2022 Qube Research & Technologies Ltd23,384$291K0.0%N/A0.050% 2/10/2022 Massachusetts Financial Services Co. MA468,797$5.84M0.0%-0.7%0.993% 2/8/2022 Swiss National Bank27,500$342K0.0%+34.1%0.058% 2/1/2022 Qube Research & Technologies Ltd23,384$291K0.0%N/A0.050% 1/31/2022 Commonwealth Equity Services LLC22,832$284K0.0%+69.4%0.048% 12/14/2021 UBS Asset Management Americas Inc.1,483,319$46.35M0.0%+15.2%3.142% BREAKING: The House just passed 3 pro-crypto bills! (Ad)THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Discover the under-the-radar project I believe will skyrocket as a result.11/15/2021 Point72 Hong Kong Ltd1,602$50K0.0%N/A0.003% 11/15/2021 Cubist Systematic Strategies LLC21,755$680K0.0%+26.5%0.046% 11/15/2021 California State Teachers Retirement System13,524$423K0.0%-9.5%0.029% 11/15/2021 Rock Springs Capital Management LP362,359$11.32M0.2%-5.2%0.769% 11/15/2021 Morgan Stanley756,787$23.65M0.0%+472.6%1.607% 11/12/2021Credit Suisse AG6,950$216K0.0%N/A0.015% 11/12/2021 Geode Capital Management LLC249,172$7.79M0.0%+11.6%0.529% 11/10/2021 Goldman Sachs Group Inc.8,659$271K0.0%-53.5%0.018% 11/10/2021 Citigroup Inc.24,268$758K0.0%-67.9%0.052% 11/10/2021 Rafferty Asset Management LLC36,936$1.15M0.0%-25.8%0.078% (Data available from 1/1/2016 forward) PRLD Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of PRLD shares? During the previous two years, 38 institutional investors and hedge funds held shares of Prelude Therapeutics. The most heavily invested institutionals were FMR LLC ($15.86M), Boxer Capital LLC ($10.97M), Vanguard Group Inc. ($4.82M), Boxer Capital Management LLC ($2.18M), Price T Rowe Associates Inc. MD ($1.31M), Jacobs Levy Equity Management Inc. ($850K), and Renaissance Technologies LLC ($809K).Learn more on Prelude Therapeutics' institutional investors. What percentage of Prelude Therapeutics' stock is owned by institutional investors? 79.72% of Prelude Therapeutics' stock is owned by institutional investors. Learn more on PRLD's institutional investor holdings. Which institutional investors have been buying Prelude Therapeutics' stock? Of the 31 institutional investors that purchased Prelude Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Boxer Capital Management LLC ($1.71M), Jacobs Levy Equity Management Inc. ($648.81K), Renaissance Technologies LLC ($437.60K), Millennium Management LLC ($302.03K), Two Sigma Advisers LP ($252.10K), Two Sigma Investments LP ($174.91K), and Rhumbline Advisers ($154.83K). How much institutional buying is happening at Prelude Therapeutics? Institutional investors have bought a total of 4,547,101 shares in the last 24 months. This purchase volume represents approximately $5.98M in transactions. Which of Prelude Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Prelude Therapeutics stock in the last 24 months: Geode Capital Management LLC ($187.39K), Price T Rowe Associates Inc. MD ($68.40K), Bridgeway Capital Management LLC ($65.10K), Massachusetts Financial Services Co. MA ($55.03K), Deutsche Bank AG ($43.18K), Northern Trust Corp ($22.99K), and Charles Schwab Investment Management Inc. ($16.05K). How much institutional selling is happening at Prelude Therapeutics? Institutional investors have sold a total of 458,135 shares in the last 24 months. This volume of shares sold represents approximately $475.07K in transactions. Related Companies Contineum Therapeutics Major Shareholders DBV Technologies Major Shareholders Mereo BioPharma Group Major Shareholders Jade Biosciences Major Shareholders Lexeo Therapeutics Major Shareholders Puma Biotechnology Major Shareholders Allogene Therapeutics Major Shareholders Tvardi Therapeutics Major Shareholders Galectin Therapeutics Major Shareholders Neumora Therapeutics Major Shareholders This page (NASDAQ:PRLD) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access